The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer
Open accessAbstract
Purpose: Ixabepilone (BMS-247550) is an epothilone analog that optimizes the properties of naturally occurring epothilone B. Natural epothilones and their analogs promote tumor cell death by binding to tubulin and stabilizing microtubules, causing apoptosis. This international phase II trial assessed the activity of ixabepilone in patients with metastatic breast cancer (MBC) that was resistant to taxane therapy. Patients and Methods: MBC patients, who had experienced disease progression while receiving or within 4 months of taxane therapy (6 months if adjuvant taxane only), and who had a taxane as their last regimen, received ixabepilone (1- or 3-hour infusion of 50 mg/m 2 or 3-hour infusion of 40 mg/m 2 every 3 weeks). Results: Of 49 patients treated with 40 mg/m 2 ixabepilone during 3 hours, 35 (73%) had experienced disease progression within 1 month of their last taxane dose. The response rate was 12% (95% CI, 4.7% to 26.5%). All responses (n = 6) were partial; five of six patients had not responded to prior taxane therapy. In responders, the median response duration was 10.4 months. In 20 patients (41%), stable disease was the best outcome. Median time to progression was 2.2 months (95% CI, 1.4 to 3.2 months); median survival was 7.9 months. For treated patients across all cohorts (intent-to-treat population), the response rate was also 12% (eight of 66). Treatment-related adverse events in the study were manageable and primarily grade 1/2. Treatment-related neuropathy was mostly sensory and mild to moderate. Conclusion: Ixabepilone (40 mg/m 2 as a 3-hour infusion every 3 weeks) demonstrates promising antitumor activity and an acceptable safety profile in patients with taxane-resistant MBC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
CLOPPER, C. J., & PEARSON, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,003
Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., & O'Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,153
Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast Cancer
Blum, J. L., Jones, S. E., Buzdar, A. U., LoRusso, P. M., Kuter, I., Vogel, C., Osterwalder, B., Burger, H.-U., Brown, C. S., & Griffin, T. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.485 · Cited by 783
Gehan, E. A. (1961) · Journal of Chronic Diseases · doi:10.1016/0021-9681(61)90060-1 · Cited by 667
Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer
Jones, S. E., Erban, J., Overmoyer, B., Budd, G. T., Hutchins, L., Lower, E., Laufman, L., Sundaram, S., Urba, W. J., Pritchard, K. I., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.027 · Cited by 547
Lee, F. Y., Borzilleri, R. M., Fairchild, C. R., Kim, S., Long, B. H., Raventós-Suárez, C., Vite, G. D., Rose, W. C., & Kramer, R. A. (2001) · PubMed · Cited by 453
Gennari, A., Conte, P., Rosso, R., Orlandini, C., & Bruzzi, P. (2005) · Cancer · doi:10.1002/cncr.21359 · Cited by 280
Winer, E. P., Berry, D. A., Woolf, S., Duggan, D., Kornblith, A., Harris, L. N., Michaelson, R. A., Kirshner, J. A., Fleming, G. F., Perry, M. C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.048 · Cited by 270
Low, J. A., Wedam, S. B., Lee, J. J., Berman, A. W., Brufsky, A., Yang, S. X., Poruchynsky, M. S., Steinberg, S. M., Mannan, N., Fojo, T., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.024 · Cited by 215
A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer.
Valero, V, Jones, S. E., Von Hoff, D. D., Booser, D. J., Mennel, R. G., Ravdin, P. M., Holmes, F. A., Rahman, Z., Schottstaedt, M. W., Erban, J. K., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3362 · Cited by 212
Self-citationSeidman, A. D., Tiersten, A., Hudis, C., Gollub, M., Barrett, S., Yao, T. J., Lepore, J., Gilewski, T., Currie, V, & Crown, J. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.10.2575 · Cited by 203
Galsky, M. D., Small, E. J., Oh, W. K., Chen, I., Smith, D. C., Colevas, A. D., Martone, L., Curley, T., DeLaCruz, A., Scher, H. I., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.042 · Cited by 189
Smith, R. E., Brown, A. M., Mamounas, E. P., Anderson, S., Lembersky, B. C., Atkins, J. H., Shibata, H. R., Báez, L., DeFusco, P. A., Davila, E., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3403 · Cited by 151
Abraham, J., Agrawal, M., Bakke, S., Rutt, A., Edgerly, M., Balis, F. M., Widemann, B. C., Davis, L., Damle, B. D., Sonnichsen, D. S., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.063 · Cited by 133
Self-citationChemotherapy: What Progress in the Last 5 Years?
Hamilton, A. L., & Hortobágyi, G. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.034 · Cited by 104
Confidence Limits for Probability of Response in Multistage Phase II Clinical Trials
Atkinson, E. N., & Brown, B. W. (1985) · Biometrics · doi:10.2307/2531294 · Cited by 101
Carpenter, J. T., Roche, H. H., Campone, M., Colomer, R., Jagiełło-Gruszfeld, A., Moore, L., D’Amore, M., Kong, S., Boni, J. P., & Baselga, J. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.564 · Cited by 99
Self-citation
Cited by
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,584
Microtubules and resistance to tubulin-binding agents
Kavallaris, M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2803 · Cited by 1,120
Chemotherapy-induced peripheral neurotoxicity (CIPN): An update
Argyriou, A. A., Bruna, J., Marmiroli, P., & Cavaletti, G. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.04.012 · Cited by 568
Perez, E. A. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0366 · Cited by 521
Thomas, E. S., Gomez, H. L., Li, R. K., Chung, H.-C., Fein, L. E., Chan, V. F., Jassem, J., Pivot, X. B., Klimovsky, J. V., de Mendoza, F. H., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.6557 · Cited by 481
Self-citation
Metadata
- Authors
- Thomas, E., Tabernero, J., Fornier, M., Conté, P., Fumoleau, P., Lluch, A., Vahdat, L. T., Bunnell, C. A., Burris, H. A., Viens, P., Baselga, J., Rivera, E., Guarneri, V., Poulart, V., Klimovsky, J., Lebwohl, D., & Martin, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-08-10
- Volume
- 25
- Issue
- 23
- Pages
- 3399-3406
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2140837341
- Cited by
- 290
- References
- 19
- FWCI
- 21.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.